1.33 USD
+0.03 (+2.31%)
1.3 USD
-0.03 (-2.26%)
Overall SSKN gets a fundamental rating of 1 out of 10. We evaluated SSKN against 185 industry peers in the Health Care Equipment & Supplies industry. SSKN may be in some trouble as it scores bad on both profitability and health. SSKN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
SSKN had negative earnings in the past year.
In the past year SSKN has reported a negative cash flow from operations.
In the past 5 years SSKN always reported negative net income.
In multiple years SSKN reported negative operating cash flow during the last 5 years.
1.2 Ratios
SSKN has a worse Return On Assets (-35.94%) than 61.62% of its industry peers.
SSKN's Return On Equity of -840.18% is on the low side compared to the rest of the industry. SSKN is outperformed by 84.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.94% | ||
| ROE | -840.18% | ||
| ROIC | N/A |
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SSKN's Gross Margin of 57.76% is in line compared to the rest of the industry. SSKN outperforms 57.84% of its industry peers.
SSKN's Gross Margin has declined in the last couple of years.
SSKN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.76% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
2. Health
2.1 Basic Checks
SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SSKN has more shares outstanding
The number of shares outstanding for SSKN has been reduced compared to 5 years ago.
Compared to 1 year ago, SSKN has a worse debt to assets ratio.
2.2 Solvency
SSKN has an Altman-Z score of -11.16. This is a bad value and indicates that SSKN is not financially healthy and even has some risk of bankruptcy.
SSKN has a worse Altman-Z score (-11.16) than 80.00% of its industry peers.
A Debt/Equity ratio of 10.22 is on the high side and indicates that SSKN has dependencies on debt financing.
SSKN has a Debt to Equity ratio of 10.22. This is amonst the worse of the industry: SSKN underperforms 86.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.16 |
ROIC/WACCN/A
WACC12.17%
2.3 Liquidity
SSKN has a Current Ratio of 0.95. This is a bad value and indicates that SSKN is not financially healthy enough and could expect problems in meeting its short term obligations.
SSKN has a Current ratio of 0.95. This is amonst the worse of the industry: SSKN underperforms 87.03% of its industry peers.
SSKN has a Quick Ratio of 0.95. This is a bad value and indicates that SSKN is not financially healthy enough and could expect problems in meeting its short term obligations.
SSKN has a worse Quick ratio (0.75) than 85.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.75 |
3. Growth
3.1 Past
SSKN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.38%.
Looking at the last year, SSKN shows a decrease in Revenue. The Revenue has decreased by -5.19% in the last year.
Measured over the past years, SSKN shows a small growth in Revenue. The Revenue has been growing by 1.22% on average per year.
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%
3.2 Future
Based on estimates for the next years, SSKN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.14% on average per year.
The Revenue is expected to grow by 2.23% on average over the next years.
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue Next Year-9.3%
Revenue Next 2Y-1.15%
Revenue Next 3Y2.23%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SSKN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SSKN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SSKN's earnings are expected to grow with 17.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.43%
EPS Next 3Y17.14%
5. Dividend
5.1 Amount
No dividends for SSKN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.33
+0.03 (+2.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners19.58%
Inst Owner Change0%
Ins Owners0.18%
Ins Owner Change-0.24%
Market Cap7.83M
Revenue(TTM)30.98M
Net Income(TTM)-11.04M
Analysts85
Price Target7.55 (467.67%)
Short Float %6.12%
Short Ratio0.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.02%
Min EPS beat(2)-104.6%
Max EPS beat(2)8.56%
EPS beat(4)1
Avg EPS beat(4)-94.34%
Min EPS beat(4)-271.14%
Max EPS beat(4)8.56%
EPS beat(8)2
Avg EPS beat(8)-98.86%
EPS beat(12)4
Avg EPS beat(12)-57.78%
EPS beat(16)7
Avg EPS beat(16)-39.57%
Revenue beat(2)0
Avg Revenue beat(2)-14.84%
Min Revenue beat(2)-17.42%
Max Revenue beat(2)-12.25%
Revenue beat(4)1
Avg Revenue beat(4)-8.34%
Min Revenue beat(4)-17.42%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-8.04%
Revenue beat(12)4
Avg Revenue beat(12)-5.63%
Revenue beat(16)6
Avg Revenue beat(16)-2.84%
PT rev (1m)-7.5%
PT rev (3m)-7.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.74%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.96 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.67
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.26
BVpS0.22
TBVpS-0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.94% | ||
| ROE | -840.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.76% | ||
| FCFM | N/A |
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score3
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.81% | ||
| Cap/Sales | 5.36% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | -11.16 |
F-Score3
WACC12.17%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)69.64%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.08%
EPS Next Y29.66%
EPS Next 2Y21.43%
EPS Next 3Y17.14%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.19%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-21.23%
Revenue Next Year-9.3%
Revenue Next 2Y-1.15%
Revenue Next 3Y2.23%
Revenue Next 5YN/A
EBIT growth 1Y-4.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78.21%
EBIT Next 3Y84%
EBIT Next 5YN/A
FCF growth 1Y47.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.99%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%
STRATA SKIN SCIENCES INC / SSKN FAQ
What is the fundamental rating for SSKN stock?
ChartMill assigns a fundamental rating of 1 / 10 to SSKN.
What is the valuation status for SSKN stock?
ChartMill assigns a valuation rating of 0 / 10 to STRATA SKIN SCIENCES INC (SSKN). This can be considered as Overvalued.
How profitable is STRATA SKIN SCIENCES INC (SSKN) stock?
STRATA SKIN SCIENCES INC (SSKN) has a profitability rating of 1 / 10.
Can you provide the financial health for SSKN stock?
The financial health rating of STRATA SKIN SCIENCES INC (SSKN) is 0 / 10.
What is the expected EPS growth for STRATA SKIN SCIENCES INC (SSKN) stock?
The Earnings per Share (EPS) of STRATA SKIN SCIENCES INC (SSKN) is expected to grow by 29.66% in the next year.